Health Care · Biological Products, (No Diagnostic Substances)

RLAY Relay Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 181236495 filings
Russell 2000

RLAY at a glance

Relay Therapeutics, Inc. (RLAY, SEC CIK 1812364) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Relay Therapeutics, Inc. (RLAY) reported revenue of $15.4 million (up 53.4% from FY2024) and a net loss of $276.5 million. Diluted EPS was -$1.61.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Relay Therapeutics, Inc. (RLAY) shares worth $1.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Patel Sanjiv on November 19, 2026 of 48,202 shares at $16.13 per share.
  • In the last 90 days, RLAY insiders reported 0 open-market purchases ($0) and 14 open-market sales ($120.7M) on Form 4, a net sale of $120.7M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$15.4M
+53.4% vs prior year
Insiders · 90 days
0 buys · 14 sells
Net −$120.7M
13F holders
28 funds
$1.2B · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • FDA clinical holds risk, with trials subject to suspension due to safety concerns or regulatory noncompliance impacting lead candidate development
  • Enrollment delays from competition with other therapies and limited eligible patients constrain trial timelines and regulatory approvals
  • Dependence on third-party CROs and diagnostic partners, which may fail to meet contractual or regulatory requirements, delaying trials and companion diagnostics approval
  • Competition for patient enrollment from other oncology trials, including Pfizer’s selective-CDK4 inhibitor in metastatic breast cancer combination study
  • High operational risk from novel mechanism drug candidates requiring extensive R&D and potential unknown adverse effects raising development costs and regulatory hurdles

Management Discussion & Analysis

  • Revenue $15.4M in 2025, up $5.3M YoY from $10.0M in 2024, primarily from Elevar Agreement milestones
  • Net loss $276.5M in 2025 vs $337.7M in 2024; operating expenses down to $318.1M from $382.5M; R&D $261.4M vs $319.1M, G&A $56.7M vs $76.6M
  • Best performing segment: License revenue from Elevar Agreement $15.4M in 2025; worst: Research & Development with $261.4M expense in 2025
  • Cash, cash equivalents, investments $554.5M as of Dec 31, 2025; raised $218.2M net in Sept 2024 offering; no share sales under $250M ATM facility; no disclosed dividends or buybacks
  • Management expects significant continued operating losses; cash runway into 2029; key risks include clinical trial progress, capital raising, regulatory approvals, and geopolitical/economic uncertainties

AI summary of the RLAY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New regulatory risk: BIOSECURE Act enacted December 18, 2025, potentially restricting WuXi AppTec arrangements from 2027 or later
  • Most material operational update: WuXi AppTec’s 1260H designation litigation, preliminary injunction granted August 7, 2026
  • Clinical risk: FDA may require a companion diagnostic for zovegalisib in biomarker-defined populations
  • Financial risk: $238.7 million net loss and $2.3 billion accumulated deficit as of September 30, 2026
  • Funding risk: $463.0 million remaining at-the-market common-stock capacity, subject to dilution risk

Management Discussion & Analysis

  • Quarterly revenue $0 vs $0 YoY, with no product sales
  • Net loss $81.7M vs $74.1M YoY, operating loss $90.2M vs $80.4M
  • R&D expense $77.1M vs $68.3M, clinical-trial costs $45.2M vs $34.0M
  • Cash, equivalents and investments $848.6M, operating cash outflow $169.2M through nine months
  • May offering generated $296.8M net; cash expected to fund operations into 2029, with continued financing needs ahead

AI summary of the RLAY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full financial details and management commentary contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $0, net loss $81.7M, or $0.37 per share, reflecting continued clinical-stage cash burn
  • Cash, equivalents and investments $848.6M, up from $554.5M at year-end, with funding expected into 2029
Filed Aug 6, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • ATM equity program expanded from $250M to $462.98M, enabling up to $212.98M of additional stock sales
  • Approximately $162.98M already sold under the agreement, indicating substantial prior equity financing

Item EX-99.1: Item EX-99.1

  • ATM equity-sales authorization increased from $250 million to $462,978,049, expanding potential financing capacity
  • Additional share issuance creates dilution risk for existing shareholders and possible financing for operations or pipeline development

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full results and management commentary available in Exhibit 99.2

Item EX-99.2: Item EX-99.2

  • Q2 revenue $0.4M, R&D $76.5M, and net loss $83.7M, reflecting accelerating clinical investment
  • Cash, equivalents and investments $910.9M after $316M gross follow-on proceeds, supporting operations into 2029
Filed Jun 9, 2026Full analysis →

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Authorized common shares increased from 300 million to 450 million
  • Stockholder approval received at the 2026 Annual Meeting

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Class III directors Douglas S. Ingram and Claire Mazumdar re-elected through 2029
  • Executive compensation approved advisory basis, 143,849,919 votes for

AI summaries of RLAY 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RLAY

Don't miss the next RLAY filing

  • Alerts as it files. A push when RLAY files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RLAY, by share count.
  • Ask anything. An AI agent that reads every RLAY filing and answers with sources.

RLAY alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Patel SanjivSellNov 19, 2026$16.13
Catinazzo ThomasSellNov 18, 2026$16.51
Bergstrom Donald ASellNov 18, 2026$16.51
Catinazzo ThomasSellOct 28, 2026$18.62
Bergstrom Donald ASellOct 28, 2026$18.62
Rahmer PeterSellOct 28, 2026$18.62
Patel SanjivSellOct 7, 2026$18.10
Catinazzo ThomasSellOct 6, 2026$19.26

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$25.5M$10.0M$15.4M
Operating Income--$372.5M-$302.7M
Net Income-$342.0M-$337.7M-$276.5M
Op. Margin--3722.1%-1971.6%
Net Margin-1338.7%-3374.7%-1800.6%
Balance Sheet
Total Assets-$871.3M$621.3M
Equity-$777.8M$567.1M
ROE--43.4%-48.8%
Per Share
EPS$-2.79$-2.36$-1.61
Cash Flow
Operating CF--$249.1M-$235.5M
CapEx$4.1M$2.0M$410K

Source: XBRL data in Relay Therapeutics, Inc. (RLAY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RLAY share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RLAY shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$1.20B
Q2 202630$1.69B
Q1 202629$523.5M
Q4 202524$404.4M
Q3 202527$241.1M
Q2 202528$186.4M
Q1 202526$106.3M
Q4 202422$139.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 214 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RLAY filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Oct 30, 2026--
4Oct 30, 2026--
4Oct 30, 2026--
4Oct 8, 2026--
4Oct 8, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
SC 13GAug 6, 2026-
4Jul 30, 2026--
4Jul 30, 2026--
4Jul 30, 2026--
4Jul 8, 2026--
4Jul 8, 2026--

Related Health Care companies

All Health Care →

RLAY SEC filings: frequently asked questions

Are RLAY insiders buying or selling?

In the last 90 days, Relay Therapeutics, Inc. (RLAY) officers, directors and 10% owners reported no open-market purchases and 14 open-market sales worth $120.7 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold RLAY stock?

As of September 30, 2026, the largest Relay Therapeutics, Inc. (RLAY) holders among the 13F filers tracked by SignalX were BlackRock ($301.4 million), State Street Corp ($165.2 million), Vanguard Capital Management LLC ($162.7 million), T. Rowe Price Group ($119.7 million), Dimensional Fund Advisors ($57.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was RLAY's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Relay Therapeutics, Inc. (RLAY) reported revenue of $15.4 million (up 53.4% from FY2024) and a net loss of $276.5 million. Diluted EPS was -$1.61. The figures come from the XBRL data in the 10-K.

What are the main risks in RLAY's latest 10-K?

In the 10-K filed February 26, 2026, Relay Therapeutics, Inc. (RLAY) flagged: FDA clinical holds risk, with trials subject to suspension due to safety concerns or regulatory noncompliance impacting lead candidate development. Enrollment delays from competition with other therapies and limited eligible patients constrain trial timelines and regulatory approvals. (AI summary of the Risk Factors section.)

What did RLAY report in its latest 8-K?

Relay Therapeutics, Inc. (RLAY) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest RLAY SEC filings?

Relay Therapeutics, Inc. (RLAY) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 20, 2026.

What is RLAY's SEC CIK number?

Relay Therapeutics, Inc. (RLAY)'s SEC Central Index Key (CIK) is 1812364. EDGAR lists every RLAY filing under that number.

Ask anything about RLAY

The research agent reads RLAY's filings, financials, insider trades and 13F holders, then answers with sources.